| Issue Date |
Title |
Author(s) |
| 25-Oct-2022 |
Bifunctional anti-PD-L1/TGF-beta RII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial |
Liu, Dan;Zhou, Jun;Wang, Yongsheng;Li, Mingjun;Jiang, Haiping;Liu, Yunpeng;Yin, Xianli;Ge, Minghua;Xiang, Xiaojun;Ying, Jieer;Huang, Jian;Zhang, Yan-qiao;Cheng, Ying;Huang, Zhigang;Yuan, Xianglin;Han, Weiqing;Yan, Dong;Wang, Xinshuai;Liu, Pan;Wang, Linna;Zhang, Xiaojing;Luo, Suxia;Liu, Tianshu;Shen, Lin |
| Apr-2021 |
Enhanced tumour penetration and prolonged circulation in blood of polyzwitterion-drug conjugates with cell-membrane affinity |
Chen, Siqin;Zhong, Yin;Fan, Wufa;Xiang, Jiajia;Wang, Guowei;Zhou, Quan;Wang, Jinqiang;Geng, Yu;Sun, Rui;Zhang, Zhen;Piao, Ying;Wang, Jianguo;Zhuo, Jianyong;Cong, Hailin;Jiang, Haiping;Ling, Jun;Li, Zichen;Yang, Dingding;Yao, Xin;Xu, Xiao;Zhou, Zhuxian;Tang, Jianbin;Shen, Youqing |
| 4-Feb-2022 |
Identifying Actionable Variants Using Capture-Based Targeted Sequencing in 563 Patients With Non-Small Cell Lung Carcinoma |
Jiang, Haiping;Wang, Yinan;Xu, Hanlin;Lei, Wei;Yu, Xiaoyun;Tian, Haiying;Meng, Cong;Wang, Xueying;Zhao, Zicheng;Jin, Xiangfeng |
| 17-Apr-2020 |
PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC |
Wang, Xiuchao;Li, Xin;Wei, Xunbin;Jiang, Haiping;Lan, Chungen;Yang, Shengyu;Wang, Han;Yang, Yanhui;Tian, Caijuan;Xu, Zanmei;Zhang, Jiangyan;Hao, Jihui;Ren, He |
| 14-Aug-2020 |
Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial |
Jiang, Haiping;Zheng, Yulong;Qian, Jiong;Mao, Chenyu;Xu, Xin;Li, Ning;Xiao, Cheng;Wang, Huan;Teng, Lisong;Zhou, Hui;Wang, Shuyan;Zhu, Donglei;Peng, Bo;Shen, Lin;Xu, Nong |
| May-2020 |
Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy |
Zhou, Quan;Dong, Chengyuan;Fan, Wufa;Jiang, Haiping;Xiang, Jiajia;Qiu, Nasha;Piao, Ying;Xie, Tao;Luo, Yingwu;Li, Zichen;Liu, Fusheng;Shen, Youqing |
